SCHEMBL5483666

SCHEMBL5483666

Nc1nc(-c2ccc(NC(=O)Nc3ccccc3)cc2)cn2ccnc12

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHB4 P54760 6/20 0.56
AURKA O14965 5/20 0.55
KDM4E B2RXH2 3/20 0.54
ALDH1A1 P00352 3/20 0.54
RAB9A P51151 2/20 0.54
LMNA P02545 1/20 0.54
POLB P06746 1/20 0.54
MAPT P10636 1/20 0.54
TMIGD3 P0DMS9 4/20 0.51
ADORA3 P0DMS8 1/20 0.51
NPC1 O15118 1/20 0.49
CYP1A2 P05177 1/20 0.49
GLA P06280 1/20 0.49
GAA P10253 1/20 0.49
HPGD P15428 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
HSD17B10 Q99714 1/20 0.49
ADORA2A P29274 2/20 0.47
ADORA1 P30542 1/20 0.47
MEN1 O00255 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5408059 0.82 ADORA1 (0.68) AURKAKDM4EALDH1A1RAB9ATMIGD3
SCHEMBL5478336 0.77 RAB9A (0.59) EPHB4AURKAKDM4EALDH1A1RAB9A
SCHEMBL5478356 0.75 EPHB4 (0.59) EPHB4AURKA
SCHEMBL5482196 0.73 AURKA (0.79) EPHB4AURKA
SCHEMBL5486441 0.73 EPHB4 (0.61) EPHB4AURKAKDM4EALDH1A1RAB9A
SCHEMBL5478026 0.72 EPHB4 (0.60) EPHB4AURKAKDM4EALDH1A1RAB9A
SCHEMBL6202976 0.72 EPHB4 (0.84) EPHB4
SCHEMBL6514368 0.71 EPHB4 (0.62) EPHB4AURKAKDM4EALDH1A1RAB9A
SCHEMBL5485600 0.71 AURKA (0.75) EPHB4AURKA
SCHEMBL5477225 0.71 EPHB4 (0.62) EPHB4AURKAKDM4EALDH1A1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7312341-B2 6-aryl-imidazo[1,2-a] pyrazin-8-ylamines, method of making, and method of use thereof CGI PHARMACEUTICALS, INC. (US) 2007-12-25 US disclosed
US-20040067951-A1 6-aryl-imidazo[1,2-a] pyrazin-8-ylamines, method of making, and method of use thereof GILEAD CONNECTICUT, INC. 2004-04-08 US disclosed
WO-2004022562-A1 6-ARYL-IMIDAZO[1,2-a]PYRAZIN-8-YLAMINES, METHOD OF MAKING, AND METHOD OF USE THEREOF CELLULAR GENOMICS, INC. (US) 2004-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040067951-A1 6-aryl-imidazo[1,2-a] pyrazin-8-ylamines, method of making, and method of use thereof MAP3K8, PRKACA, MAP3K1 EPHB4 4062/4885AURKA 207/4885KDM4E 2361/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.